A whitepaper was recently released by researchers at the USC Schaeffer Center and the Aspen Institute. The authors discuss half a dozen recommendations relating to HTAs (Health Technology Assessments) in the United States, which could lead to changes in the pricing of prescription drugs. Implementing an HTA, similar to ICER (Institute for Clinical and Economic Review), could provide limit costs for patients and improve equity.
The authors note, “Health technology assessment (HTA) can help achieve the dual health policy goals of ensuring affordability and encouraging innovation. It represents a formal, systematic and transparent multidisciplinary process that uses explicit methods and available evidence to determine the value of a health technology. The dimensions of value most often include clinical effectiveness, safety, costs and economic implications and may include ethical, social, cultural and legal issues, organizational and environmental aspects, as well as wider implications for the patient, relatives, caregivers and population.” Read more here.
(Source: Lakdawalla et al., USC Schaeffer, 2/9/21)
